// App-Quantinova.ai

: Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.

Researchers

Presenter

  • Bertrand F. TOMBAL

Principal Investigators

  • Andrew J. Armstrong

  • Jeffrey Kent Barrus

  • Tomasz M. Beer

  • Simon Chowdhury

  • Christopher P. Evans

  • Axel Heidenreich

  • Celestia S. Higano

  • Tomomi Kamba

  • Ping Lin

  • Natalia Nikolayeva

  • Jennifer Sugg

  • Joyce Leta Steinberg

  • Mary Ellen Taplin

  • Fred Saad

Medical Centers

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, NC

  • Astellas Pharma, Inc., Northbrook, IL

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of California, Davis School of Medicine, Sacramento, CA

  • Department of Hematology and Oncology, University Hospital, Rostock, Germany

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

  • Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

  • Amgen Inc, South San Francisco, CA

  • Astellas Pharma Europe, Leiden, Netherlands

  • Dana-Farber Cancer Institute, Boston, MA

  • Centre Hospitalier de lUniversite de Montreal/CRCHUM, University of Montreal, Montreal, QC, Canada

Locations

  • Belgium

  • United States

  • United Kingdom

  • Germany

  • Japan

  • Netherlands

  • Canada

Companies

  • Astellas Pharma Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Coronary Artery Disease

  • Myocardial infarction

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • NCT02003924

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved